Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Boschetti

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
Inflammatory Bowel Diseases|January 28, 2015
Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's diseaseGilles Boschetti, Patrick Garnero, Driffa Moussata, et al.
Annals of Surgery|October 25, 2016
A Perioperative Clinical Pathway Can Dramatically Reduce Failure-to-rescue Rates After Cytoreductive Surgery for Peritoneal Carcinomatosis: A Retrospective Study of 666 Consecutive CytoreductionsGuillaume Passot, Delphine Vaudoyer, Laurent Villeneuve, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2021
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapyLuc Manlay, Gilles Boschetti, Bruno Pereira, et al.
Gastroenterology|May 2, 2016
Mouse and Human Liver Contain Immunoglobulin A-Secreting Cells Originating From Peyer's Patches and Directed Against Intestinal AntigensLudovic Moro-Sibilot, Pascal Blanc, Morgan Taillardet, et al.
Inflammatory Bowel Diseases|September 26, 2017
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational StudyXavier Roblin, Gilles Boschetti, Gérard Duru, et al.
Journal of Crohn'S & Colitis|July 2, 2016
Gut Inflammation in Mice Triggers Proliferation and Function of Mucosal Foxp3+ Regulatory T Cells but Impairs Their Conversion from CD4+ T CellsGilles Boschetti, Reem Kanjarawi, Emilie Bardel, et al.
Annals of Surgical Oncology|March 27, 2014
Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosisGuillaume Passot, Benoît You, Gilles Boschetti, et al.
Journal of Crohn'S & Colitis|June 4, 2018
Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept StudyStephane Paul, Nicolas Williet, Thomas Di Bernado, et al.
The American Journal of Gastroenterology|August 26, 2010
A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalizationAbderrahim Oussalah, Ludovic Evesque, David Laharie, et al.
European Journal of Immunology|November 1, 2015
Plasmacytoid dendritic cells are dispensable for noninfectious intestinal IgA responses in vivoLudovic Moro-Sibilot, Sebastien This, Pascal Blanc, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Inflammatory Bowel Diseases|January 28, 2015
Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's diseaseGilles Boschetti, Patrick Garnero, Driffa Moussata, et al.
Annals of Surgery|October 25, 2016
A Perioperative Clinical Pathway Can Dramatically Reduce Failure-to-rescue Rates After Cytoreductive Surgery for Peritoneal Carcinomatosis: A Retrospective Study of 666 Consecutive CytoreductionsGuillaume Passot, Delphine Vaudoyer, Laurent Villeneuve, et al.
Alimentary Pharmacology & Therapeutics|April 28, 2021
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapyLuc Manlay, Gilles Boschetti, Bruno Pereira, et al.
Gastroenterology|May 2, 2016
Mouse and Human Liver Contain Immunoglobulin A-Secreting Cells Originating From Peyer's Patches and Directed Against Intestinal AntigensLudovic Moro-Sibilot, Pascal Blanc, Morgan Taillardet, et al.
Inflammatory Bowel Diseases|September 26, 2017
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational StudyXavier Roblin, Gilles Boschetti, Gérard Duru, et al.
Journal of Crohn'S & Colitis|July 2, 2016
Gut Inflammation in Mice Triggers Proliferation and Function of Mucosal Foxp3+ Regulatory T Cells but Impairs Their Conversion from CD4+ T CellsGilles Boschetti, Reem Kanjarawi, Emilie Bardel, et al.
Annals of Surgical Oncology|March 27, 2014
Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosisGuillaume Passot, Benoît You, Gilles Boschetti, et al.
Journal of Crohn'S & Colitis|June 4, 2018
Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept StudyStephane Paul, Nicolas Williet, Thomas Di Bernado, et al.
The American Journal of Gastroenterology|August 26, 2010
A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalizationAbderrahim Oussalah, Ludovic Evesque, David Laharie, et al.
European Journal of Immunology|November 1, 2015
Plasmacytoid dendritic cells are dispensable for noninfectious intestinal IgA responses in vivoLudovic Moro-Sibilot, Sebastien This, Pascal Blanc, et al.
Pageof 7